• Platform & Pipeline
    • Opportunity
    • CAR T-Cell Therapy
    • Pipeline
    • Clinical Trials and Expanded Access
  • Patients
    • Experience
    • Stiff Person Syndrome
    • Myasthenia Gravis
    • Multiple Sclerosis
    • Lupus Nephritis
    • Systemic Sclerosis
  • Inside Kyverna
    • Leadership
    • Mission & Values
  • Education & Events
    • Events
    • Publications
    • Videos
  • Investors
  • News
  • Careers
  • Contact
← Back

Browse Jobs

Clinical

Associate Director, Clinical Data Management

Remote
View

Director of Training, Global Medical Affairs

Remote
View

Executive Director, Clinical Data Management

Remote
View

Medical Director/Sr. Medical Director, Clinical Development

Remote
View

Sr. Clinical Scientist

Remote
View

Sr. Director, Clinical Scientist

Remote
View

Commercial

Executive Director, Head of Cellular Therapy Operations

Remote
View

Sr. Director, Marketing Promotions

Emeryville, CA
View

Sr. Manager / Assoc. Director, Forecasting & Insights

Emeryville, CA
View

VP, Commercial Operations

Remote
View

Executive

Senior Executive Assistant

Emeryville, CA
View

G&A

Associate Director, SEC Reporting & Technical Accounting

Remote
View

Paralegal, Contract Management & Legal Operations

Emeryville, CA
View

Manufacturing

Executive Director, Supply Chain & Strategic Sourcing

Remote
View

Partnerships and Alliances

Sr. Director, Business Development

Remote
View

Quality

Sr. Director, Quality Systems

Emeryville, CA
View

Regulatory Affairs

Executive Director, Regulatory Affairs

Remote
View

Research/Pre-Clinical

Sr. Scientific Advisor CAR T Technologies

Remote
View

Tech Ops

Process Engineer, Process Development

Emeryville, CA
View

Links

  • Home
  • Platform & Pipeline
  • Patients
  • Inside Kyverna
  • Education & Events
  • Investors
  • Careers
  • Contact

About

Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases.

Our lead CAR T-cell therapy candidate mivocabtagene (miv-cel, KYV-101), is advancing through clinical development with sponsored clinical trials across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff person syndrome, multiple sclerosis, and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis.

Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.

FOLLOW US ON SOCIAL

  • Privacy Policy (US)
  • Privacy Policy (EU/UK)

Designed by Elegant Themes | Powered by WordPress